These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28295521)

  • 1. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
    Suh HY; Ahn JY; Park MY; Youn JI
    J Dermatol; 2018 Mar; 45(3):332-333. PubMed ID: 28295521
    [No Abstract]   [Full Text] [Related]  

  • 2. Ustekinumab Demonstrates Lower Uveitis Risk in Moderate to Severe Psoriasis Patients Compared with Tumor Necrosis Factor-α Inhibitors.
    Bang CH; Oh HJ; Kim YH; Jung JH; Lee JH; Park YM; Han JH
    Acta Derm Venereol; 2024 Sep; 104():adv34206. PubMed ID: 39248291
    [No Abstract]   [Full Text] [Related]  

  • 3. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
    Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
    Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
    Gkini MA; Bewley AP
    Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
    [No Abstract]   [Full Text] [Related]  

  • 5. Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab.
    Vestita M; Guida S; Mazzoccoli S; Loconsole F; Foti C
    Eur J Dermatol; 2015; 25(3):272-3. PubMed ID: 25786592
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
    Lund T; Thomsen SF
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
    Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
    Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.
    Membrillo de Novales FJ; Ávila Jiménez A; Merino Meléndez L; Torres León J; López Soberón E; Fe Marqués A; Pérez Mochales JF
    J Clin Rheumatol; 2015 Apr; 21(3):171-3. PubMed ID: 25807103
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
    Takamura S; Takahashi A; Inoue Y; Teraki Y
    J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe disseminated Nocardia infection associated with ustekinumab treatment for psoriasis.
    Couture-Cossette A; Morand M; Vinh DC; Gratton M; Martin P
    Br J Dermatol; 2019 Jul; 181(1):194-195. PubMed ID: 30657168
    [No Abstract]   [Full Text] [Related]  

  • 12. A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.
    Wang J; Zhan Q; Zhang L
    Hum Vaccin Immunother; 2016; 12(2):431-7. PubMed ID: 26528924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lewis-Sumner syndrome associated with infliximab therapy for psoriasis.
    Oliveira KF; Martins GA; Galvão KR; Kurizky PS
    An Bras Dermatol; 2017; 92(1):156-157. PubMed ID: 28225983
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
    Leonardi CL
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases.
    Wu J; Smogorzewski J
    Dermatol Ther; 2021 May; 34(3):e14883. PubMed ID: 33594811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case of recurrent severe cellulitis and cutaneous candidiasis during psoriasis treatment with ustekinumab.
    Miyachi H; Nakamura Y; Wakabayashi S; Iwasawa MT; Oikawa A; Watanabe A; Matsue H
    J Dermatol; 2017 Aug; 44(8):e206-e207. PubMed ID: 28432713
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab for psoriasis.
    Gottlieb AB
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
    Pinheiro RR; Duarte B; Ferreira A; Cabete J
    Eur J Dermatol; 2018 Feb; 28(1):89-91. PubMed ID: 29400282
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis.
    Wahie S; Alexandroff A; Reynolds NJ
    Clin Exp Dermatol; 2006 May; 31(3):460-1. PubMed ID: 16681606
    [No Abstract]   [Full Text] [Related]  

  • 20. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.
    Loft ND; Skov L; Iversen L; Gniadecki R; Dam TN; Brandslund I; Hoffmann HJ; Andersen MR; Dessau RB; Bergmann AC; Andersen NM; Andersen PS; Bank S; Vogel U; Andersen V
    Pharmacogenomics J; 2018 May; 18(3):494-500. PubMed ID: 28696418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.